REG - Eco Animal Health Gp - ECOVAXXIN® MS EU marketing authorisation granted

ECO Animal HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251222:nRSV3682Ma&default-theme=true

RNS Number : 3682M  Eco Animal Health Group PLC  22 December 2025

22 December 2025

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

EU marketing authorisation granted for ECOVAXXIN® MS

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that the European Commission has
adopted a decision granting EU marketing authorisation (MA) for ECOVAXXIN®
MS, the Company's poultry vaccine against Mycoplasma synoviae.

 

The MA has been issued over a month earlier than anticipated following the
Committee for Medicinal Products for Veterinary Use's Positive Opinion in
November 2025
(https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=7833038&lang=en-GB&companycode=uk-lac&v=)
.

 

ECOVAXXIN® MS provides active immunisation of future layer and breeder
chickens from four weeks of age, helping to reduce air-sac and foot-pad
lesions and egg production losses caused by Mycoplasma synoviae infections.
 The infection causes economic loss, especially in laying hens, and the
number of eggs produced by affected layers can be reduced by 5-10%.

 

The Company will issue an update to the market in early 2026 to provide
further details on its plans for the EU commercial launch of ECOVAXXIN® MS.

 

David Hallas, Chief Executive Officer of ECO Animal Health, said: "We are
delighted to have received EU marketing authorisation for ECOVAXXIN MS, over a
month ahead of schedule. This is a key milestone for ECO, enabling the first
commercial launch from our innovative R&D portfolio, and reflects the
high-quality work from our R&D, regulatory, marketing,
and technical teams.

 

"We look forward to updating the market early in 2026 to provide more detail
on our plans for the commercial launch of this important vaccine."

 

-Ends-

Contacts

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGBWPUPAGBB



            Copyright 2019 Regulatory News Service, all rights reserved